930 results match your criteria: "Centre for Medicine Use and Safety[Affiliation]"
Age Ageing
January 2025
Faculty of Medicine Nursing and Health Sciences, Peninsula Clinical School, National Centre for Healthy Ageing, Monash University, Ngarnga Centre, Frankston, VIC, Australia.
Diabetes Care
January 2025
Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Canada.
Objective: To determine whether glucagon-like peptide 1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 (SGLT-2) inhibitors, separately, compared with dipeptidyl peptidase 4 (DPP-4) inhibitors are associated with a reduced risk of cirrhosis and other adverse liver outcomes among patients with type 2 diabetes.
Research Design And Methods: With an active comparator, new-user approach, we conducted a cohort study using the U.K.
Curr Pharm Teach Learn
December 2024
Division of Practice Advancement and Clinical Education, Clinical Education, UNC Eshelman School of Pharmacy, 121 Karpen Hall, 1 University Heights, Asheville, NC 28804, United States; UNC School of Medicine and UNC Health Sciences at MAHEC, 123 Hendersonville Rd, Asheville, NC 28803, United States; Center for Healthy Aging, Mountain Area Health Education Center, 123 Hendersonville Rd, Asheville, NC 28803, United States. Electronic address:
Introduction: The population of older adults is expanding globally, but there remains a lack of healthcare professionals trained to meet growing care needs. The primary objective of this study was to compare the top three to four factors driving interest vs. lack of interest in geriatrics among pharmacy students in the United States (US) vs.
View Article and Find Full Text PDFTher Adv Drug Saf
December 2024
Faculty of Pharmacy, Université Laval, CEVQ, 1050 Chemin Ste-Foy, Quebec, QC G1S 4L8, Canada.
Background: As the number of medications increases, the appropriateness of polypharmacy may become questionable due to the heightened risk of medication-related harm.
Objectives: (1) To investigate the relationship between the number of current medications used by older adults and three indicators of potentially inappropriate polypharmacy: (a) the mean number of potentially inappropriate medications (PIMs), (b) the average count of drug-drug interactions, and (c) the anticholinergic burden; (2) To characterize the population-based burden of potentially inappropriate polypharmacy by calculating the proportion of individuals with these indicators.
Design: We conducted a population-based observational study using the Quebec Integrated Chronic Disease Surveillance System.
Br J Clin Pharmacol
December 2024
School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Continuation of opioids at transitions of care increases the risk of long-term opioid use and related harm. To our knowledge, no study has examined the implementability of opioid deprescribing interventions at transitions of care. Our scoping review aimed to identify the type of opioid deprescribing interventions employed at transitions of care and assess the implementability of tested interventions.
View Article and Find Full Text PDFGlob Health Res Policy
December 2024
Appleton Institute, Physical Activity Research Group, Central Queensland University, Rockhampton, QLD, Australia.
Background: Prevention of type 2 diabetes is becoming an urgent public health concern in low and middle-income countries (LMICs). However, there is currently no evidence of a cost-effective approach of health behaviour interventions from community settings in low-income countries like Nepal. Therefore, this study aimed to assess the within-trial economic evaluation of a health behaviour intervention compared with usual care for managing type 2 diabetes in a community setting in Nepal.
View Article and Find Full Text PDFHeart Lung Circ
December 2024
Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Vic, Australia; Department of Epidemiology, Baker Heart and Diabetes Institute, Melbourne, Vic, Australia.
J Am Geriatr Soc
December 2024
Harvey Cushing/John Hay Whitney Medical Library, Yale University, New Haven, Connecticut, USA.
Cancer Epidemiol
February 2025
Health Economics and Policy Evaluation Research (HEPER), Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia; School of Public Health and Preventative Medicine, Monash University, Melbourne, Australia. Electronic address:
Purpose: Breast cancer exerts a considerable burden on an individual's health, but also impacts society more broadly through lost work productivity. This study aimed to measure the quality of life and productivity burden among Australian females of working age diagnosed with breast cancer in 2022.
Methods: A Markov lifetable model was simulated twice; the initial simulation followed the progression of Australian females diagnosed with breast cancer in 2022 using current population incidence rates, whilst the second simulation hypothetically assumed there were no females living with breast cancer.
Clin Pharmacokinet
January 2025
Certara Predictive Technologies (CPT), Sheffield, UK.
Background: Predicting metabolic drug-drug interactions (DDIs) via cytochrome P450 enzymes (CYP) is essential in drug development, but controversy has reemerged recently about whether in vitro-in vivo extrapolation (IVIVE) using static models can replace dynamic models for some regulatory filings and label recommendations.
Objective: The aim of this study was to determine if static and dynamic models are equivalent for the quantitative prediction of metabolic DDIs arising from competitive CYP inhibition.
Methods: Drug parameter spaces were varied to simulate 30,000 DDIs between hypothetical substrates and inhibitors of CYP3A4.
J Am Geriatr Soc
December 2024
Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
BMC Health Serv Res
December 2024
School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
Background: Given growing demand for hip and knee arthroplasty and unsustainable resource requirements, safe and efficient models of care are critical. This study aims to determine the impact on healthcare costs of implementing an enhanced short-stay model of care (ESS-MOC) for arthroplasty at a national level.
Methods: A budget impact analysis was conducted for the years 2023-2030 in the setting of Australian publicly and privately funded hospitals performing hip or knee arthroplasty.
Intern Med J
December 2024
National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Background: Antimicrobial stewardship (AMS) guidelines now recommend antifungal stewardship (AFS) interventions to improve the management of invasive fungal diseases (IFDs). AFS programmes have not been reported in Australia.
Aims: To determine the monitoring of antifungal use, AFS strategies and targets, and barriers to AFS implementation in Australian hospitals.
Pharmacoeconomics
December 2024
Health Economics and Policy Evaluation Research (HEPER) Group, Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia.
Background And Objective: Current Australian cardiovascular disease (CVD) prevention guidelines calculate 5-year CVD risk and recommend treatment when risk crosses specific thresholds. This may leave risk factors untreated for people with a low short-term (i.e.
View Article and Find Full Text PDFFuture Cardiol
November 2024
Victorian Heart Institute, Monash University, Melbourne, Victoria, Australia.
Int J Clin Pharm
February 2025
Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
Lancet Diabetes Endocrinol
December 2024
Department of Diabetes and Population Health, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia; School of Life Sciences, La Trobe University, Melbourne, VIC, Australia.
Background: Population-based incidence data on young-adult-onset type 1 diabetes and type 2 diabetes are limited. We aimed to examine secular trends in the incidence of diagnosed type 1 diabetes and type 2 diabetes with an age of onset between 15 and 39 years.
Methods: In this multicountry aggregate data analysis, we assembled eight administrative datasets from high-income jurisdictions and countries (Australia, Denmark, Finland, Hungary, Japan, Scotland, South Korea, and Spain [Catalonia]) that had appropriate data available from an international diabetes consortium (GLOBODIAB) describing incidence by diabetes type among people aged 15-39 years from 2000 to 2020.
Respirology
November 2024
Medical School, Curtin University, Perth, Western Australia, Australia.
Globally, more than 1.2 billion inhalers are purchased for asthma and chronic obstructive pulmonary disease (COPD) annually. In Australia and New Zealand, pressurized metered dose inhalers (pMDIs) are the leading delivery device prescribed and pMDI salbutamol can be purchased over the counter in Australia.
View Article and Find Full Text PDFJAMA Netw Open
November 2024
Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia.
Importance: The increased use of gabapentinoids has been most pronounced in older people who are also susceptible to hip fractures.
Objective: To investigate the overall association between gabapentinoids and the risk of hip fractures and the stratified association across age groups, frailty status, and history of chronic kidney disease.
Design, Setting, And Participants: This was a case-case-time-control study in patients hospitalized for hip fracture in Victoria, Australia, between March 1, 2013, and June 30, 2018, with at least 1 prescription for a gabapentinoid before fracture.
BMJ Qual Saf
November 2024
Monash Addiction Research Centre (MARC), Eastern Health Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Frankston, Victoria, Australia.
Health Sci Rep
November 2024
Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences Monash University Parkville Victoria Australia.
Background And Aims: This Australian population-based study investigated statin intensity after hospitalization for ischemic stroke in a matched cohort of people living with and without dementia.
Methods: We identified all patients aged ≥ 30 years hospitalized in the state of Victoria, Australia, for ischemic stroke from July 1, 2013 to April 30, 2018 from the Victorian Admitted Episodes Data set. People with dementia were matched 1:4 for sex, 5-year age group and index date ± 90 days with people without dementia.
J Aerosol Med Pulm Drug Deliv
November 2024
Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD (GRIAC), University of Groningen, Groningen, The Netherlands.
Pulm Pharmacol Ther
October 2023
Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, 381 Royal Parade, Melbourne, Victoria, 3052, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Background: Long-term changes in medication dispensings post cystic fibrosis transmembrane conductance regulator (CFTR) modulator initiation have not been described. Our study aimed to investigate changes in medication use following the initiation of modulator therapy in people with cystic fibrosis (PwCF) in Australia.
Methods: Using a 10% sample of the Australian Pharmaceutical Benefits Scheme (PBS) data between 2013 and 2022, linear regression was used to analyse dispensings in PwCF who initiated any modulator (cases) and matched PwCF controls not dispensed a modulator.
Environ Int
November 2024
Climate, Air Quality Research (CARE) Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia. Electronic address:
Drugs Aging
November 2024
Faculty of Medicine and Health, School of Pharmacy, The University of Sydney, Rm 401, Badham Building A16, Camperdown, 2006, Sydney, NSW, Australia.
Approximately one in three older adults (aged 65 years and over) experience pain, negatively impacting their quality of life. Opioid analgesics are commonly prescribed to manage pain; however, balancing the benefits and harms of these high-risk analgesics can be challenging for both healthcare professionals and patients. This is particularly true for older adults, as factors such as polypharmacy, age-related physiological changes and cognitive decline may impact upon opioid safety and efficacy.
View Article and Find Full Text PDF